Clinical trials: Prevention of Zika Infection
Zika Virus, Zika Virus Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated…
- Trial name
- NCT03425149
- Testing
- VLA1601
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH